Exhibition Review | Cellgene Bioscience Shines at BIO CHINA 2026
From March 12 to 14, 2026, the 11th ENMORE Biological Industry Exhibition (BIOCHINA 2026) was grandly held at Suzhou International Expo Center. With the theme of "Fusion Forward", this conference gathered more than 30,000 professionals from over 40 countries and regions around the world, set up 250 professional forums, and invited more than 900 heavyweight speakers, creating a global biopharmaceutical industry event connecting the whole world.
As a deep practitioner in the field of biopharmaceutical quality and safety testing, Cellgene Bioscience made a wonderful appearance with its core products and solutions, and discussed new opportunities for industrial development with industry colleagues worldwide.
A Stunning Debut with a Popular Booth
During the exhibition, Cellgene Bioscience’s booth (E3B20) was extremely popular, with a continuous flow of professional customers in the pharmaceutical and biopharmaceutical fields, and on-site consultations and technical exchanges were ongoing. Customers showed great interest in our exhibited series of biopharmaceutical quality control products such as host cell protein (HCP)/DNA (HCD)/RNA (HCR) residual detection kits and other exogenous risk factors, as well as characteristic CRO services such as HCP-specific product customization and antibody coverage analysis. This fully demonstrated Cellgene Bioscience's full-chain technical barriers and comprehensive service capabilities from core raw material R&D to finished product delivery.
At the exhibition site, many customers came to consult with practical problems in ELISA experiments, including core pain points such as poor linearity, unqualified recovery rate, and insufficient antibody coverage. Relying on 20 years of in-depth accumulation of ELISA technology, Cellgene Bioscience accurately answered customers' questions one by one, solved experimental bottlenecks, and won unanimous recognition from on-site customers with professional strength.
Roundtable Forum: Discussing Innovation in Biopharmaceutical Raw Material Production and Manufacturing
One of the major highlights of this conference was that the founder of Cellgene Bioscience was invited to participate in the roundtable forum on "Innovation in the Production and Manufacturing of Biopharmaceutical Raw Materials". The forum focused on the cutting-edge topic of the current industry - how to improve the independent and controllable capacity of biopharmaceutical raw materials through technological innovation under the wave of domestic substitution.
At the forum, the founder and many industry experts conducted in-depth discussions around four core directions: gene delivery, cell-free synthesis, cell culture, and quality control technology, and jointly explored the future prospect of biopharmaceutical raw material production and manufacturing.
1.Gene Delivery: Breaking Carrier Limits to Achieve Precise Targeting
Gene delivery is the foundation of cell and gene therapy, and is currently witnessing a number of key technological breakthroughs.
The innovation of gene delivery is evolving from "being able to deliver in" to "precisely delivering to the target". In the future, it will focus more on breaking through carrier capacity, improving targeting, and the diversified development of non-viral vectors.
2.Cell Culture: Three Waves Converging—Automation, Intelligence, and Biomimetics
The future of cell culture lies in high-efficiency and high-consistency operations assisted by automation and AI, the real restoration of the in vivo environment supported by bionic materials, and the in-depth understanding and precise regulation of cell development mechanisms.
3. Quality Control Technology: From "Post-inspection" to "Full-process Assurance"
In the production of biopharmaceutical raw materials, quality is not inspected but designed. The forum discussed the four core dimensions of quality control technology in depth:
Dimension | Key Technologies | Core Value |
Quality by Design | Critical Quality Attributes, Critical Process Parameters, Design Space | Guarantee quality from the source design and establish a proactive quality system |
Process Analytical Technology | Spectroscopy, Chromatography, Biosensors, Multivariate Data Analysis | Real-time monitoring of key parameters to achieve immediate feedback and closed-loop control |
AI and Automation | Machine Learning, Deep Learning, Digital Twin | Realize precise regulation, intelligent decision-making and full-process automation |
New Sensors | Microfluidic Chips, 3D Printing Platforms, Intelligent Sensors | Achieve miniaturization, low sample volume, and real-time non-destructive monitoring of multiple indicators simultaneously |
The future of biomanufacturing quality control is a more efficient, robust and reliable production system driven by data, supported by intelligent decision-making and guaranteed by real-time monitoring.
Voice of Cellgene Bioscience: Contributing "Cellgene Bioscience Strength" in the Wave of Domestic Substitution
In the concluding speech of the roundtable forum, the founder of Cellgene Bioscience shared three core insights:
01 Technological Innovation is the Fundamental Driving Force of Domestic Substitution
Genuine domestic substitution is not a simple "import copy", but a breakthrough from underlying technologies. Since its establishment, Cellgene Bioscience has always adhered to independent R&D, realizing full-process independent control from antigen enrichment and antibody library construction to kit debugging. At present, our HCP detection products have covered the main expression systems of biopharmaceuticals worldwide, among which Saccharomyces cerevisiae HCP, Hansenula polymorpha HCP and other products are unique in China.
02 Quality is Derived from Design, While Testing Ensures Safety
"The quality and safety of biopharmaceuticals is not an icing on the cake, but the lifeline of the industry." Through 15 years of technological accumulation, Cellgene Bioscience has provided domestic pharmaceutical enterprises with accurate, stable and customizable testing solutions, building the cornerstone of "precision testing" for drug safety from the source.
03 Open Cooperation to Co-build an Industrial Ecology
As an upstream supplier in the biopharmaceutical industry chain, Cellgene Bioscience is willing to join hands with more innovative pharmaceutical enterprises to jointly promote the high-quality development of China's biopharmaceutical industry through technology sharing and joint R&D.
Innovation Leads to the Future
When pharmaceutical enterprises select products for quality control links, the qualifications of the original source factory and the professional degree of vertical in-depth cultivation have become core decision criteria. Customers prefer specialized manufacturers focusing on a single field rather than "general store"-style enterprises with a wide range of categories. Cellgene Bioscience adheres to the "small and refined" development positioning, only focusing on and deeply cultivating the HCP track, with extremely specialized technical accumulation, accurately locating quality control pain points, and efficiently solving the quality control problems of pharmaceutical customers.
Although the three-day exhibition was short, it was a fruitful experience. We would like to thank new and old customers for visiting Cellgene Bioscience's booth, industry colleagues for their recognition and encouragement, and the organizer Etrade Medical for building this high-quality communication platform.
Standing at the new starting point of the high-quality development of the biopharmaceutical industry, Cellgene Bioscience will continue to deepen its cultivation in the field of biopharmaceutical quality and safety testing, driven by technological innovation and guided by customer needs, and strive to become a reliable "hidden champion" in the wave of domestic substitution.
Just like the theme of this conference "Fusion Forward" - integrating all forces and leading industrial development. Cellgene Bioscience is willing to join hands with all partners to jointly promote China's biopharmaceutical industry towards a better future.
